(HealthDay)—For patients with advanced lung cancer, prompting oncologists via e-mail successfully improved both the rate and timing of outpatient code status documentation in patients' electronic health records, according ...
Jan 5, 2013
0
0
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical ...
Dec 10, 2012
0
0
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell – DLBCL ...
Dec 10, 2012
0
0
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine, a standard drug used for chemotherapy today in women with previously treated metastatic breast cancer, ...
Dec 7, 2012
0
1
(Medical Xpress)—Ongoing research at the Methodist Cancer Center could reveal whether metastatic breast cancer patients with BRCA gene mutations are particularly responsive to a drug regimen that includes Veliparib, an ...
Sep 20, 2012
0
0
Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab ...
Sep 6, 2012
0
0
Adding the monoclonal antibody bavituximab to docetaxel chemotherapy doubles overall response rate and improves progression-free survival and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) ...
Sep 6, 2012
0
0
(HealthDay) -- Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea (DN) in patients receiving chemotherapy containing a platinum-based ...
Aug 22, 2012
0
0
Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies.
Aug 13, 2012
0
0
(HealthDay) -- In older patients with mantle-cell lymphoma, a rituximab-based chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]) followed by maintenance therapy with rituximab ...
Aug 9, 2012
0
0
